Clinical Trials – Leads and Recommendations

As we come across any information on Clinical Trials, we will post them here. We also encourage you to share any information with us by posting on our Forum by clicking here or sending us a message via our Contact Us page. Please Share!

 

11/20/2019

Click here for PDF of current trials updated November 20, 2019

  1. Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
    Study Number: NCT03206177
    Learn More
  2. Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
    Study Number: NCT03651206
    Learn More
  3. Trial on Trabectedin In The Treatment of Advanced Uterine And Ovarian Carcinosarcoma (CS) MITO 26
    Study Number: NCT02993705
    Learn More
  4. Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
    Study Number: NCT00687687
    Learn More
  5. Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma
    Study Number: NCT04149275
    Learn More
  6. Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)
    Study Number: NCT02203760
    Learn More
  7. Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)
    Study Number: NCT03933761
    Learn More
  8. Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
    Study Number: NCT04106414
    Learn More
  9. Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
    Study Number: NCT00025506
    Learn More
  10. Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
    Study Number: NCT00502203
    Learn More

 

 


6-25-2018

Below is a list of Clinical Trials found on clinicaltrials.gov that accept patients with carcinosarcoma and are currently recruiting.  

Please visit a study’s website for more information about inclusion and exclusion criteria.

To find detailed information on a study, please go to web address for each trial. If the link does not work, go to https://www.clinicaltrials.gov/ and enter the NCT number (study number).

 

 

  1. A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204)

 

2. A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies. 

 

3. A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949in Subjects With Advanced or Metastatic Solid Tumors

 

  1. Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 (MITO 26)

 

  1. Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

 

  1. A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

 

  1. Vorinostat (SAHA) in Uterine Sarcoma

 

  1. A study of Nivolumab in Selected Uterine Cancer Patients

 

  1. Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

 

  1. Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endomentrial Cancer (SAVE)

 

  1. Nivolumab and Ipilimumab in Treating Patients with Rare Tumors